MA46268B1 - Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma - Google Patents
Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gammaInfo
- Publication number
- MA46268B1 MA46268B1 MA46268A MA46268A MA46268B1 MA 46268 B1 MA46268 B1 MA 46268B1 MA 46268 A MA46268 A MA 46268A MA 46268 A MA46268 A MA 46268A MA 46268 B1 MA46268 B1 MA 46268B1
- Authority
- MA
- Morocco
- Prior art keywords
- phosphatidylinositol
- gamma
- isoindol
- ylamino
- thiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne certains nouveaux composés (y compris des sels pharmaceutiquement acceptables de ceux-ci) qui inhibent l'activité de la phosphatidylinositol 3-kinase gamma (pi3kd), et l'activité de la phosphatidylinositol 3-kinase gamma (??3??), leur utilité dans le traitement et/ou la prévention d'affections cliniques comprenant les maladies respiratoires, telles que l'asthme et la broncho-pneumopathie chronique obstructive (bpco), leur utilisation en thérapie, des compositions pharmaceutiques les contenant et des procédés pour préparer ces composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398006P | 2016-09-22 | 2016-09-22 | |
| PCT/EP2017/073916 WO2018055040A1 (fr) | 2016-09-22 | 2017-09-21 | Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46268A MA46268A (fr) | 2019-07-31 |
| MA46268B1 true MA46268B1 (fr) | 2020-08-31 |
Family
ID=59966739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46268A MA46268B1 (fr) | 2016-09-22 | 2017-09-21 | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10961236B2 (fr) |
| EP (1) | EP3515910B1 (fr) |
| JP (1) | JP6765516B2 (fr) |
| KR (1) | KR102226098B1 (fr) |
| CN (1) | CN109715623A (fr) |
| AR (1) | AR109706A1 (fr) |
| AU (1) | AU2017331940B2 (fr) |
| BR (1) | BR112019004719A2 (fr) |
| CA (1) | CA3036304A1 (fr) |
| CL (1) | CL2019000707A1 (fr) |
| CO (1) | CO2019003440A2 (fr) |
| CR (1) | CR20190200A (fr) |
| CY (1) | CY1123346T1 (fr) |
| DK (1) | DK3515910T3 (fr) |
| DO (1) | DOP2019000073A (fr) |
| EA (1) | EA036176B1 (fr) |
| EC (1) | ECSP19027780A (fr) |
| ES (1) | ES2818583T3 (fr) |
| HR (1) | HRP20201175T1 (fr) |
| HU (1) | HUE051634T2 (fr) |
| IL (1) | IL265298B (fr) |
| JO (1) | JOP20190052A1 (fr) |
| LT (1) | LT3515910T (fr) |
| MA (1) | MA46268B1 (fr) |
| MX (2) | MX2019003194A (fr) |
| PE (1) | PE20190909A1 (fr) |
| PH (1) | PH12019500615A1 (fr) |
| PL (1) | PL3515910T3 (fr) |
| PT (1) | PT3515910T (fr) |
| RS (1) | RS60764B1 (fr) |
| SI (1) | SI3515910T1 (fr) |
| SV (1) | SV2019005857A (fr) |
| TW (1) | TW201813967A (fr) |
| UA (1) | UA123558C2 (fr) |
| WO (1) | WO2018055040A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11078204B2 (en) | 2018-11-13 | 2021-08-03 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| US11396502B2 (en) | 2018-11-13 | 2022-07-26 | Incyte Corporation | Substituted heterocyclic derivatives as PI3K inhibitors |
| US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| WO2022017371A1 (fr) * | 2020-07-21 | 2022-01-27 | 中国医药研究开发中心有限公司 | Composé hétérocylique présentant une double activité inhibitrice de phosphatidylinositol 3-kinase δ et γ et son utilisation médicale |
| WO2022023456A1 (fr) | 2020-07-29 | 2022-02-03 | Astrazeneca Ab | Compositions pharmaceutiques comprenant des microparticules nano-intégrées et procédés d'utilisation |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4405726B2 (ja) * | 2000-12-21 | 2010-01-27 | ブリストル−マイヤーズ スクイブ カンパニー | Ｔｅｃファミリーチロシンキナーゼのチアゾリルインヒビター |
| GB0305152D0 (en) * | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| GB0320197D0 (en) * | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
| AU2006258101A1 (en) * | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| US7928140B2 (en) * | 2007-08-02 | 2011-04-19 | Amgen Inc. | Benzothiazole PI3 kinase modulators for cancer treatment |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| WO2013012915A1 (fr) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Composés hétérocycliques et leurs utilisations |
| CA2846431A1 (fr) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Composes heterocycliques et leurs utilisations |
| WO2013052699A2 (fr) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Nouveaux inhibiteurs de quinoxaline de la voie pi3k |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| TW201446767A (zh) | 2013-02-15 | 2014-12-16 | Almirall Sa | 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物 |
| WO2015001491A1 (fr) | 2013-07-02 | 2015-01-08 | Rhizen Pharmaceuticals Sa | Inhibiteurs de protéine kinase pi3k, en particulier inhibiteurs delta et/ou gamma |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| CA2951370A1 (fr) | 2014-06-27 | 2015-12-30 | Rhizen Pharmaceuticals Sa | Derives substitues de chromene en tant qu'inhibiteurs doubles selectifs des inhibiteurs de la pi3 delta proteine kinase et de la pi3 gamma proteine kinase |
-
2017
- 2017-06-16 JO JOP/2019/0052A patent/JOP20190052A1/ar unknown
- 2017-09-21 MX MX2019003194A patent/MX2019003194A/es unknown
- 2017-09-21 MA MA46268A patent/MA46268B1/fr unknown
- 2017-09-21 PE PE2019000702A patent/PE20190909A1/es unknown
- 2017-09-21 KR KR1020197010973A patent/KR102226098B1/ko active IP Right Grant
- 2017-09-21 JP JP2019515477A patent/JP6765516B2/ja not_active Expired - Fee Related
- 2017-09-21 AU AU2017331940A patent/AU2017331940B2/en not_active Ceased
- 2017-09-21 CN CN201780057289.2A patent/CN109715623A/zh active Pending
- 2017-09-21 PL PL17772381.4T patent/PL3515910T3/pl unknown
- 2017-09-21 SI SI201730357T patent/SI3515910T1/sl unknown
- 2017-09-21 EA EA201990664A patent/EA036176B1/ru not_active IP Right Cessation
- 2017-09-21 LT LTEP17772381.4T patent/LT3515910T/lt unknown
- 2017-09-21 CA CA3036304A patent/CA3036304A1/fr not_active Abandoned
- 2017-09-21 TW TW106132359A patent/TW201813967A/zh unknown
- 2017-09-21 BR BR112019004719A patent/BR112019004719A2/pt not_active IP Right Cessation
- 2017-09-21 PT PT177723814T patent/PT3515910T/pt unknown
- 2017-09-21 DK DK17772381.4T patent/DK3515910T3/da active
- 2017-09-21 EP EP17772381.4A patent/EP3515910B1/fr active Active
- 2017-09-21 US US16/332,620 patent/US10961236B2/en active Active
- 2017-09-21 ES ES17772381T patent/ES2818583T3/es active Active
- 2017-09-21 RS RS20201077A patent/RS60764B1/sr unknown
- 2017-09-21 WO PCT/EP2017/073916 patent/WO2018055040A1/fr unknown
- 2017-09-21 HU HUE17772381A patent/HUE051634T2/hu unknown
- 2017-09-21 CR CR20190200A patent/CR20190200A/es unknown
- 2017-09-21 UA UAA201903648A patent/UA123558C2/uk unknown
- 2017-09-22 AR ARP170102631A patent/AR109706A1/es unknown
-
2019
- 2019-03-11 IL IL265298A patent/IL265298B/en active IP Right Grant
- 2019-03-19 CL CL2019000707A patent/CL2019000707A1/es unknown
- 2019-03-20 MX MX2021004748A patent/MX2021004748A/es unknown
- 2019-03-20 DO DO2019000073A patent/DOP2019000073A/es unknown
- 2019-03-21 PH PH12019500615A patent/PH12019500615A1/en unknown
- 2019-03-22 SV SV2019005857A patent/SV2019005857A/es unknown
- 2019-04-08 CO CONC2019/0003440A patent/CO2019003440A2/es unknown
- 2019-04-17 EC ECSENADI201927780A patent/ECSP19027780A/es unknown
-
2020
- 2020-07-28 HR HRP20201175TT patent/HRP20201175T1/hr unknown
- 2020-09-09 CY CY20201100856T patent/CY1123346T1/el unknown
-
2021
- 2021-02-11 US US17/173,826 patent/US20210246130A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46268B1 (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| MA42292A (fr) | Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b | |
| MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| MX2010002115A (es) | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. | |
| MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
| MA34449B1 (fr) | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase | |
| NO20083059L (no) | Pyrimidinderivater | |
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA38358A1 (fr) | Formulations de composés organiques | |
| BRPI0607214B8 (pt) | derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA33563B1 (fr) | 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl | |
| MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| MA38697A1 (fr) | 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7 | |
| BR112012020060B8 (pt) | uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
| US20170029388A1 (en) | Treatment of Neurodegenerative Diseases with Asparagine Endopeptidase (AEP) Inhibitors and Compositions Related Thereto | |
| DK3124025T3 (en) | COMBINATION BETWEEN 3 - [(3 - {[4- (4-MORPHOLINYLMETHYL) -1H-PYRROL-2-YL] -METHYLENE} -2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL) -METHYL ] -1,3-THIAZOLIDIN-2,4-DION AND AN EGFR-TYROKINASE INHIBITOR |